《大医生》编辑部官网欢迎您!
加入收藏 | 设为主页 
A 型肉毒毒素联合复方倍他米松治疗带状疱疹后神经痛的 临床观察
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R752.1+2

基金项目:


Clinical observation of botulinum toxin type A combined with compound betamethasone in the treatment of post-herpetic neuralgia
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 观察 A 型肉毒毒素( BTX-A)联合复方倍他米松局部注射治疗带状疱疹后神经痛( PHN)的临床疗效及安全性,为临 床提供参考。 方法 选取 2021 年 3 月至 2022 年 11 月中山市第二人民医院收治的 150 例 PHN 患者为研究对象,按照随机数字表法分为 A 组、 B 组和 C 组,各 50 例。 A 组患者行 BTX-A 局部注射治疗, B 组患者行复方倍他米松联合利多卡因治疗, C 组患者行复方倍他米松、 利多卡因联合 BTX-A 治疗。比较 3 组患者治疗效果、皮肤病生活质量指数( DLQI)评分、 β- 内啡肽( β-EP)水平、 P 物质( SP)水平 及不良反应发生情况。 结果 C 组患者整体疗效优于 A 组、 B 组( P<0.05)。 A 组与 B 组整体疗效比较,差异无统计学意义( P>0.05)。 3 组患者的总有效率比较,差异无统计学意义( P>0.05)。 3 组患者治疗后 4 周和治疗后 12 周的 DLQI 评分低于治疗前,且 C 组患者治 疗后 4 周和治疗后 12 周的 DLQI 评分低于 A 组、 B 组( P<0.05)。 3 组患者治疗后 4 周和治疗后 12 周的 β-EP 水平高于治疗前, SP 水平 低于治疗前,且 C 组患者治疗后 4 周和治疗后 12 周的 β-EP 水平高于 A 组、 B 组, SP 水平低于 A 组、 B 组( P<0.05)。 3 组患者不良反 应发生率比较,差异无统计学意义( P>0.05)。 结论 复方倍他米松、利多卡因联合 BTX-A 方案用于 PHN 患者的疗效显著,可有效缓解 疼痛,改善生活质量,且安全性理想。

    Abstract:

    Objective To observe the clinical efficacy and safety of botulinum toxin type A (BTX-A) combined with compound betamethasone local injection in the treatment of post-herpetic neuralgia (PHN), to provide reference for clinical practice. Methods 150 PHN patients admitted in Zhongshan Second People’s Hospital from March 2021 to November 2022 were selected as the research objects, and they were divided into A, B, C group by random number table method, 50 patients in each group. Patients in group A received local injection of BTX-A, patients in group B received compound betamethasone combined with lidocaine intervention, and patients in group C received compound betamethasone combined with lidocaine and BTX-A intervention. The treatment efficacy, dermatology life quality index (DLQI) score, the serum β-endorphin (β-EP), serum substance P (SP) and the occurrence of adverse reactions were compared among the three groups. Results The overall efficacy of patients in group C was better than that in group A and group B (P<0.05). There was no significant difference in overall efficacy between group A and group B (P>0.05). There was no significant difference in the total effective rate between the three groups (P>0.05). Patients in three groups had lower DLQI score at 4 weeks and 12 weeks after treatment than before treatment, and the DLQI score in group C at 4 weeks and 12 weeks after treatment was lower than that in group A and group B (P<0.05). Patients in three groups had higher β-EP levels at 4 weeks and 12 weeks after treatment than before treatment, SP levels were lower than before treatment, and the β-EP level in group C at 4 weeks and 12 weeks after treatment was higher than that in group A and group B, and the SP level was lower than that in group A and group B (P<0.05). There was no significant difference in the incidence of adverse reactions among the three groups (P>0.05). Conclusion The combination of compound betamethasone, lidocaine and BTX-A are used in patients of PHN, which has significant efficacy, can relieve pain and improve quality of life, and it has good safety.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2023-10-25
  • 出版日期: